Table 1 Clinicopathological characteristics of patients with breast cancer who were diagnosed with ductal carcinoma in situ and invasive ductal carcinoma
Characteristics | Ductal carcinoma in situ (n = 199) | Invasive ductal carcinoma (n = 914) | P value |
|---|---|---|---|
Mean age (years, ±SD) | 50.1 ± 9.4 | 49.3 ± 9.9 | 0.649 |
Mean body mass index (kg/m2, ± SD) | 23.2 ± 3.0 | 23.4 ± 3.2 | 0.745 |
History of bilateral breast cancer (n, %) | 14 (7.0) | 30 (3.3) | 0.014 |
Clinical tumor size on ultrasound (cm, ± SD) | 2.01 ± 1.7 | 2.0 ± 1.2 | 0.213 |
Pathological tumor size (cm, ± SD) | 2.2 ± 1.9 | 1.7 ± 1.1 | 0.109 |
Estrogen receptor, positive (n, %) | 135 (67.8) | 639 (69.9) | 0.379 |
Progesterone receptor, positive (n, %) | 120 (60.3) | 568 (62.1) | 0.136 |
c-erbB2 protein, positive (n, %) | 73 (36.7) | 169 (18.5) | 0.226 |
Triple-negative breast cancer (n, %) | 11 (5.5) | 85 (9.3) | 0.002 |
Adjuvant chemotherapy (n, %) | 0 | 460 (50.3) | < 0.001 |
Adjuvant radiotherapy (n, %) | 67 (33.7) | 636 (69.6) | < 0.001 |
Adjuvant hormonal therapy (n, %) | 125 (62.8) | 687 (75.2) | 0.061 |
Follow-up period (mo, ± SD) | 90.1 ± 25.3 | 88.6 ± 19.1 | 0.241 |
Locoregional recurrence (n, %) | 3 (1.5) | 17 (1.9) | 0.506 |
Distant metastasis (n, %) | 1 (0.5) | 24 (2.6) | < 0.001 |
Death (n, %) | 1 (0.5) | 9 (1.0) | 0.192 |